Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference
PALO ALTO, Calif. and MIAMI, June 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and ...
Despite what was previously thought, new research has shown that genetic changes alone cannot explain why and where tumors grow in those with genetic condition neurofibromatosis type 1 (NF-1).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback